Differentiating systemic lupus erythematosus from other diseases: Difference between revisions

Jump to navigation Jump to search
Line 10: Line 10:
Systemic lupus erythematosus (SLE) must be differentiated from other diseases that cause [[arthritis]], positive [[autoimmune]] serology, and [[Constitutional acrocyanosis|constitutional]] symptoms, such as [[rheumatoid arthritis]](RA), [[mixed connective tissue disease]] (MCTD), [[systemic sclerosis]] (SSc), [[dermatomyositis]] (DM), [[polymyositis]](PM), and other autoimmune diseases.  
Systemic lupus erythematosus (SLE) must be differentiated from other diseases that cause [[arthritis]], positive [[autoimmune]] serology, and [[Constitutional acrocyanosis|constitutional]] symptoms, such as [[rheumatoid arthritis]](RA), [[mixed connective tissue disease]] (MCTD), [[systemic sclerosis]] (SSc), [[dermatomyositis]] (DM), [[polymyositis]](PM), and other autoimmune diseases.  


===== Differetiating SLE from other diseases that cause [[arthritis]], positive [[autoimmune]] serology, and [[Constitutional acrocyanosis|constitutional]] symptoms =====
{| class="wikitable"
{| class="wikitable"
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |

Revision as of 15:10, 30 June 2017


Systemic lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Systemic lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Lupus and Quality of Life

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Differentiating systemic lupus erythematosus from other diseases On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Differentiating systemic lupus erythematosus from other diseases

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Differentiating systemic lupus erythematosus from other diseases

on Differentiating systemic lupus erythematosus from other diseases

Differentiating systemic lupus erythematosus from other diseases in the news

Blogs onDifferentiating systemic lupus erythematosus from other diseases

Directions to Hospitals Treating Systemic lupus erythematosus

Risk calculators and risk factors for Differentiating systemic lupus erythematosus from other diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Overview

Systemic lupus erythematosus (SLE) must be differentiated from other diseases that cause arthritis, positive autoimmune serology, and constitutional symptoms, such as rheumatoid arthritis(RA), mixed connective tissue disease (MCTD), systemic sclerosis (SSc), dermatomyositis (DM), polymyositis(PM), and other autoimmune diseases.

Differentiating systemic lupus erythematosus from other diseases

Systemic lupus erythematosus (SLE) must be differentiated from other diseases that cause arthritis, positive autoimmune serology, and constitutional symptoms, such as rheumatoid arthritis(RA), mixed connective tissue disease (MCTD), systemic sclerosis (SSc), dermatomyositis (DM), polymyositis(PM), and other autoimmune diseases.

Differetiating SLE from other diseases that cause arthritis, positive autoimmune serology, and constitutional symptoms
Overlapping Features Distinguishing/specific features
Rheumatoid arthritis (RA)
  • Joint deformities in RA are often more extensive, and frequently erosive on plain radiographs
  • Presence of anti-cyclic citrullinated peptides (CCP)
Rhupus
  • Patients with overlapping features of both SLE and RA
  • Serologies consistent with both SLE and RA
Mixed connective tissue disease (MCTD)
Undifferentiated connective tissue disease (UCTD)
  • Mild disease course
Systemic sclerosis (SSc)
  • Positive ANA
  • Positive anti-double-stranded DNA (dsDNA)
  • Positive anti-Smith (Sm) antibodies
Sjögren’s syndrome
  • Extra-glandular manifestations
  • Neurologic abnormalities
  • Pulmonary abnormalities
  • Positive antibodies to Ro and La antigens
  • Keratoconjunctivitis sicca
  • Xerostomia
  • Salivary gland biopsy: Focal collection or collections of tightly aggregated lymphocytes, termed lymphocytic foci, which are typically periductal
Vasculitis
  • ANA-negative
Behçet’s syndrome
  • Oral aphthae
  • Inflammatory eye disease
  • Neurologic disease
  • Vascular disease
  • Arthritis
  • Male dominancy
  • ANA-negative
Dermatomyositis (DM) and polymyositis (PM)
  • Positive ANA: In approximately 30 percent of patients
  • Gottron’s papules: A heliotrope eruption and photodistributed poikiloderma (including the shawl and V signs)
  • More overt proximal muscle weakness than SLE
  • Absence of oral ulcers, arthritis, nephritis, and hematologic abnormalities
  • Myositis-specific antibodies such as anti-Jo-1
Adult Still’s disease (ASD)
Kikuchi’s disease
  • May be associated with SLE
  • Spontaneous remission usually occurring within four months
  • Lymph node biopsy: Histiocytic cellular infiltrate
Serum sickness
  • Negative ANA
  • Self-limited
Fibromyalgia
  • SLE patients may have concomitant fibromyalgia as the prevalence of fibromyalgia in patients with systemic rheumatoid diseases is more
Infections Viruses
  • Serologic assays can be diagnostic for many of these viruses
  • EBV
    • May lead to a positive ANA[2]
Human immunodeficiency virus (HIV)
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Cytomegalovirus (CMV)
Epstein-Barr virus (EBV)
Bacterias Salmonella
Mycobacterium tuberculosis
Multiple sclerosis (MS)
  • Unilateral optic neuritis
  • Pyramidal syndrome
  • Lesions detected by magnetic resonance imaging (MRI) suggesting dissemination in space and time
Malignancies
  • Hematologic abnormalities
  • Constitutional symptoms
Thrombotic thrombocytopenic purpura (TTP)

References

  1. Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirják L, Damjanov N, Rednic S, Matucci Cerinic M (2012). ""To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity". Semin. Arthritis Rheum. 41 (4): 589–98. doi:10.1016/j.semarthrit.2011.07.010. PMID 21959290.
  2. Sculley DG, Sculley TB, Pope JH (1986). "Reactions of sera from patients with rheumatoid arthritis, systemic lupus erythematosus and infectious mononucleosis to Epstein-Barr virus-induced polypeptides". J. Gen. Virol. 67 ( Pt 10): 2253–8. doi:10.1099/0022-1317-67-10-2253. PMID 3020161.